Results 111 to 120 of about 70,383 (240)

Case report: Acute HHV6B encephalitis/myelitis post CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma

open access: yesFrontiers in Neurology
BackgroundThe development of chimeric antigen receptor (CAR)-T cell therapy has revolutionized treatment outcomes in patients with lymphoid malignancies.
Ningwen Li   +15 more
doaj   +1 more source

MOG Antibody‐Associated Optic Neuritis Masquerading as Traumatic Optic Neuropathy Following Cranial Trauma: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) is an autoimmune disorder characterized by demyelination of the central nervous system. It can impact the optic nerves, spinal cord, brain parenchyma, and brainstem, resulting in various clinical presentations such as acute disseminated encephalomyelitis (ADEM), optic ...
Yuxian Shi   +5 more
wiley   +1 more source

Case report: Hypereosinophilic atopic transverse myelitis

open access: yes, 2018
Atopic transverse myelitis is a rare disorder that is defined as a localized myelitis of an unknown cause in patients with either high immunoglobulin E (IgE) level or mite‑specific IgE or coexistent atopic disease.
Aworanti, O.W., Fasola, F.A.
core   +1 more source

Autoimmune GFAP astrocytopathy manifesting as sintilimab-induced myelitis: a Case Report and literature review

open access: yesFrontiers in Immunology
Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1), programmed cell death protein 1 ligand, and cytotoxic T-lymphocyte-associated protein 4, are important therapeutic approaches for malignancies.
Xue Ma, Xing Qin
doaj   +1 more source

MOG antibody-associated disease – a new entity or one of the forms of the NMO spectrum?

open access: yesAktualności Neurologiczne, 2019
Myelin oligodendrocyte glycoprotein (MOG) is a protein involved in the maintenance of the myelin structure. Recent studies have shown that serum anti-MOG antibodies are found in some of the patients who meet the diagnostic criteria for neuromyelitis ...
Dominika Czarnecka, Mariusz Stasiołek
doaj   +1 more source

Longitudinal Myelitis [PDF]

open access: yesMayo Clinic Proceedings, 2008
Nicole M, Orzechowski, Clement J, Michet
openaire   +2 more sources

Synergistic Interaction Between MALAT1/miR‐30b‐5p/BAFF Axis and Inflammatory Cytokines Underlies Rituximab‐Refractory NMOSD

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
The MALAT1/miR‐30b‐5p/BAFF axis is activated in monocytes during NMOSD onset and relapse. The MALAT1/miR‐30b‐5p/BAFF axis is activated in monocytes, thereby facilitating the release of BAFF and inflammatory cytokines (including IL‐1, IL‐6, IL‐8, and TNF‐α).
Meiqun Deng   +8 more
wiley   +1 more source

Editorial: Immune-mediated disorders of the spinal cord: Diagnosis, treatment strategies, and outcomes in the 21st century

open access: yesFrontiers in Neurology, 2022
Giulia Fadda   +3 more
doaj   +1 more source

Opposing Influences of Optic Neuritis and Transverse Myelitis on the Future Location of Relapses in MOG Antibody–Associated Disease

open access: yesBrain and Behavior
Background Studies in MS and NMOSD have shown that relapses can frequently occur in the same location as the first attack. Factors associated with this outcome in MOGAD are unclear.
Daniel Lordelo San Martin   +4 more
doaj   +1 more source

Therapeutic Plasma Exchange in the Elderly: Rare Indications but Good Tolerability

open access: yesJournal of Clinical Apheresis, Volume 41, Issue 3, June 2026.
ABSTRACT Therapeutic plasma exchange (TPE) is used for a wide range of indications and is associated with well‐described adverse events. However, no study has specifically focused on tolerance in elderly patients, despite its expected increasing use in this population. We conducted a single‐center retrospective case–control study of all patients aged ≥ 
Valentin Coirier   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy